Literature DB >> 33407723

RMRP, RMST, FTX and IPW: novel potential long non-coding RNAs in medullary thyroid cancer.

Berta Luzón-Toro1,2, Leticia Villalba-Benito1,2, Raquel María Fernández1,2, Ana Torroglosa1,2, Guillermo Antiñolo1,2, Salud Borrego3,4.   

Abstract

The relevant role of long non-coding RNAs (lncRNAs) in cancer is currently a matter of increasing interest. Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor (2-5% of all thyroid cancer) derived from the parafollicular C-cells which secrete calcitonin. About 75% of all medullary thyroid cancers are believed to be sporadic medullary thyroid cancer (sMTC), whereas the remaining 25% correspond to inherited cancer syndromes known as Multiple Endocrine Neoplasia type 2 (MEN2). MEN2 syndrome, with autosomal dominant inheritance is caused by germline gain of function mutations in RET proto-oncogene. To date no lncRNA has been associated to MEN2 syndrome and only two articles have been published relating long non-coding RNA (lncRNA) to MTC: the first one linked MALAT1 with sMTC and, in the other, our group determined some new lncRNAs in a small group of sMTC cases in fresh tissue (RMST, FTX, IPW, PRNCR1, ADAMTS9-AS2 and RMRP). The aim of the current study is to validate such novel lncRNAs previously described by our group by using a larger cohort of patients, in order to discern their potential role in the disease. Here we have tested three up-regulated (RMST, FTX, IPW) and one down-regulated (RMRP) lncRNAs in our samples (formalin fixed paraffin embedded tissues from twenty-one MEN2 and ten sMTC patients) by RT-qPCR analysis. The preliminary results reinforce the potential role of RMST, FTX, IPW and RMRP in the pathogenesis of MTC.

Entities:  

Keywords:  FTX; IPW; MEN2; MTC; RMRP; RMST; lncRNA

Mesh:

Substances:

Year:  2021        PMID: 33407723      PMCID: PMC7789680          DOI: 10.1186/s13023-020-01665-5

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  37 in total

1.  [Glioblastoma multiforme and multiple endocrine neoplasic type 2 A].

Authors:  Ruth Sánchez-Ortiga; Evangelina Boix Carreño; Oscar Moreno-Pérez; Antonio Picó Alfonso
Journal:  Med Clin (Barc)       Date:  2009-03-09       Impact factor: 1.725

Review 2.  Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.

Authors:  J R Hansford; L M Mulligan
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

3.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.

Authors:  C Eng; D Clayton; I Schuffenecker; G Lenoir; G Cote; R F Gagel; H K van Amstel; C J Lips; I Nishisho; S I Takai; D J Marsh; B G Robinson; K Frank-Raue; F Raue; F Xue; W W Noll; C Romei; F Pacini; M Fink; B Niederle; J Zedenius; M Nordenskjöld; P Komminoth; G N Hendy; L M Mulligan
Journal:  JAMA       Date:  1996-11-20       Impact factor: 56.272

Review 4.  Prader- Willi syndrome: An uptodate on endocrine and metabolic complications.

Authors:  Giovanna Muscogiuri; Gloria Formoso; Gabriella Pugliese; Rosaria Maddalena Ruggeri; Elisabetta Scarano; Annamaria Colao
Journal:  Rev Endocr Metab Disord       Date:  2019-06       Impact factor: 6.514

5.  The noncoding RNA IPW regulates the imprinted DLK1-DIO3 locus in an induced pluripotent stem cell model of Prader-Willi syndrome.

Authors:  Yonatan Stelzer; Ido Sagi; Ofra Yanuka; Rachel Eiges; Nissim Benvenisty
Journal:  Nat Genet       Date:  2014-05-11       Impact factor: 38.330

6.  lncRNA Ftx promotes aerobic glycolysis and tumor progression through the PPARγ pathway in hepatocellular carcinoma.

Authors:  Xiao Li; Qi Zhao; Jianni Qi; Wenwen Wang; Di Zhang; Zhen Li; Chengyong Qin
Journal:  Int J Oncol       Date:  2018-05-23       Impact factor: 5.650

7.  LncRNAs as Potential Therapeutic Targets in Thyroid Cancer.

Authors:  Zeeshan Javed; Faiez Ahmed Shah; Sadegh Rajabi; Qamar Raza; Zaheer Iqbal; Mukhtar Ullah; Touqeer Ahmad; Bahare Salehi; Mehdi Sharifi-Rad; Raffaele Pezzani; Farooq Yaqoob; Haleema Sadia; Marcello Iriti; Javad Sharifi-Rad; William C Cho
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01

8.  LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling.

Authors:  Hua Liu; Haoyu Deng; Yajie Zhao; Can Li; Yu Liang
Journal:  J Exp Clin Cancer Res       Date:  2018-11-21

9.  A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia.

Authors:  Svetlana Vakkilainen; Mervi Taskinen; Paula Klemetti; Eero Pukkala; Outi Mäkitie
Journal:  Front Immunol       Date:  2019-07-16       Impact factor: 7.561

10.  LncRNA FTX Contributes to the Progression of Colorectal Cancer Through Regulating miR-192-5p/EIF5A2 Axis.

Authors:  Kui Zhao; Zhenyu Ye; Yecheng Li; Chunyan Li; Xiaodong Yang; Qiang Chen; Chungen Xing
Journal:  Onco Targets Ther       Date:  2020-03-31       Impact factor: 4.147

View more
  2 in total

1.  The long non-coding RNA rhabdomyosarcoma 2-associated transcript exerts anti-tumor effects on lung adenocarcinoma via ubiquitination of SOX9.

Authors:  Yaofei Pei; Bing Zhou; Xiqiang Liu
Journal:  Ann Transl Med       Date:  2022-01

2.  Upregulation of FTX expression is associated with a poor prognosis and contributes to the progression of thyroid cancer.

Authors:  Ping Wang; Yongming Zhang; Wenping Wang; Huimin Jiang
Journal:  Oncol Lett       Date:  2021-07-18       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.